Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.

Nikolaus B Wagner; Max M Lenders; Kathrin Kühl; Lydia Reinhardt; Fiona André; Milena Dudda; Natalie Ring; Chiara Ebel; Ramon Stäger; Caroline Zellweger; Roland Lang; Michael Paar; Philipp Gussek; Georg Richtig; Suzan H Stürmer; Susanne Kimeswenger; Angela Oellinger; Andrea Forschner; Ulrike Leiter; Benjamin Weide; Maximilian Gassenmaier; Amadeus Schraag; Bernhard Klumpp; Wolfram Hoetzenecker; Carola Berking; Erika Richtig; Mirjana Ziemer; Johanna Mangana; Patrick Terheyden; Carmen Loquai; Van Anh Nguyen; Christoffer Gebhardt; Friedegund Meier; Stefan Diem; Antonio Cozzio; Lukas Flatz; Martin Röcken; Claus Garbe; Thomas K Eigentler

doi:10.1136/jitc-2021-002350

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.

Nikolaus B Wagner, Max M Lenders, Kathrin Kühl, Lydia Reinhardt, Fiona André, Milena Dudda, Natalie Ring, Chiara Ebel, Ramon Stäger, Caroline Zellweger, Roland Lang (Co-author), Michael Paar, Philipp Gussek, Georg Richtig, Suzan H Stürmer, Susanne Kimeswenger, Angela Oellinger, Andrea Forschner, Ulrike Leiter, Benjamin WeideMaximilian Gassenmaier, Amadeus Schraag, Bernhard Klumpp, Wolfram Hoetzenecker, Carola Berking, Erika Richtig, Mirjana Ziemer, Johanna Mangana, Patrick Terheyden, Carmen Loquai, Van Anh Nguyen, Christoffer Gebhardt, Friedegund Meier, Stefan Diem, Antonio Cozzio, Lukas Flatz, Martin Röcken, Claus Garbe, Thomas K Eigentler

Research output: Contribution to journal › Original Article (Journal) › peer-review

10 Citations (Web of Science)

Original language	English
Journal	JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume	9
Issue number	5
DOIs	https://doi.org/10.1136/jitc-2021-002350
Publication status	Published - 2021

Keywords

TUMOR DOUBLING TIME
COMBINED NIVOLUMAB
CANCER-PATIENTS
IPILIMUMAB
RECIST
PEMBROLIZUMAB
EXPRESSION
INDICATOR
RESECTION
KINETICS

Access to Document

10.1136/jitc-2021-002350

Cite this

Wagner, N. B., Lenders, M. M., Kühl, K., Reinhardt, L., André, F., Dudda, M., Ring, N., Ebel, C., Stäger, R., Zellweger, C., Lang, R., Paar, M., Gussek, P., Richtig, G., Stürmer, S. H., Kimeswenger, S., Oellinger, A., Forschner, A., Leiter, U., ... Eigentler, T. K. (2021). Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9(5). https://doi.org/10.1136/jitc-2021-002350

@article{7f7170f68ee94de8b185b15ffb26a378,

title = "Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.",

keywords = "TUMOR DOUBLING TIME, COMBINED NIVOLUMAB, CANCER-PATIENTS, IPILIMUMAB, RECIST, PEMBROLIZUMAB, EXPRESSION, INDICATOR, RESECTION, KINETICS",

author = "Wagner, {Nikolaus B} and Lenders, {Max M} and Kathrin K{\"u}hl and Lydia Reinhardt and Fiona Andr{\'e} and Milena Dudda and Natalie Ring and Chiara Ebel and Ramon St{\"a}ger and Caroline Zellweger and Roland Lang and Michael Paar and Philipp Gussek and Georg Richtig and St{\"u}rmer, {Suzan H} and Susanne Kimeswenger and Angela Oellinger and Andrea Forschner and Ulrike Leiter and Benjamin Weide and Maximilian Gassenmaier and Amadeus Schraag and Bernhard Klumpp and Wolfram Hoetzenecker and Carola Berking and Erika Richtig and Mirjana Ziemer and Johanna Mangana and Patrick Terheyden and Carmen Loquai and Nguyen, {Van Anh} and Christoffer Gebhardt and Friedegund Meier and Stefan Diem and Antonio Cozzio and Lukas Flatz and Martin R{\"o}cken and Claus Garbe and Eigentler, {Thomas K}",

note = "Lang: Department of Dermatology and Allergology, Paracelsus Medical University Salzburg, Salzburg, Austria; Paar: Institute of Radiology, Paracelsus Medical University Salzburg, Salzburg, Austria",

year = "2021",

doi = "10.1136/jitc-2021-002350",

language = "English",

volume = "9",

journal = "JOURNAL FOR IMMUNOTHERAPY OF CANCER",

issn = "2051-1426",

number = "5",

}

Wagner, NB, Lenders, MM, Kühl, K, Reinhardt, L, André, F, Dudda, M, Ring, N, Ebel, C, Stäger, R, Zellweger, C, Lang, R, Paar, M, Gussek, P, Richtig, G, Stürmer, SH, Kimeswenger, S, Oellinger, A, Forschner, A, Leiter, U, Weide, B, Gassenmaier, M, Schraag, A, Klumpp, B, Hoetzenecker, W, Berking, C, Richtig, E, Ziemer, M, Mangana, J, Terheyden, P, Loquai, C, Nguyen, VA, Gebhardt, C, Meier, F, Diem, S, Cozzio, A, Flatz, L, Röcken, M, Garbe, C & Eigentler, TK 2021, 'Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.', JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, no. 5. https://doi.org/10.1136/jitc-2021-002350

TY - JOUR

T1 - Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.

AU - Wagner, Nikolaus B

AU - Lenders, Max M

AU - Kühl, Kathrin

AU - Reinhardt, Lydia

AU - André, Fiona

AU - Dudda, Milena

AU - Ring, Natalie

AU - Ebel, Chiara

AU - Stäger, Ramon

AU - Zellweger, Caroline

AU - Lang, Roland

AU - Paar, Michael

AU - Gussek, Philipp

AU - Richtig, Georg

AU - Stürmer, Suzan H

AU - Kimeswenger, Susanne

AU - Oellinger, Angela

AU - Forschner, Andrea

AU - Leiter, Ulrike

AU - Weide, Benjamin

AU - Gassenmaier, Maximilian

AU - Schraag, Amadeus

AU - Klumpp, Bernhard

AU - Hoetzenecker, Wolfram

AU - Berking, Carola

AU - Richtig, Erika

AU - Ziemer, Mirjana

AU - Mangana, Johanna

AU - Terheyden, Patrick

AU - Loquai, Carmen

AU - Nguyen, Van Anh

AU - Gebhardt, Christoffer

AU - Meier, Friedegund

AU - Diem, Stefan

AU - Cozzio, Antonio

AU - Flatz, Lukas

AU - Röcken, Martin

AU - Garbe, Claus

AU - Eigentler, Thomas K

N1 - Lang: Department of Dermatology and Allergology, Paracelsus Medical University Salzburg, Salzburg, Austria; Paar: Institute of Radiology, Paracelsus Medical University Salzburg, Salzburg, Austria

PY - 2021

Y1 - 2021

KW - TUMOR DOUBLING TIME

KW - COMBINED NIVOLUMAB

KW - CANCER-PATIENTS

KW - IPILIMUMAB

KW - RECIST

KW - PEMBROLIZUMAB

KW - EXPRESSION

KW - INDICATOR

KW - RESECTION

KW - KINETICS

U2 - 10.1136/jitc-2021-002350

DO - 10.1136/jitc-2021-002350

M3 - Original Article (Journal)

C2 - 33986126

SN - 2051-1426

VL - 9

JO - JOURNAL FOR IMMUNOTHERAPY OF CANCER

JF - JOURNAL FOR IMMUNOTHERAPY OF CANCER

IS - 5

ER -